Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

Lung Cancer

Volumn 28, Issue 2, 2000, Pages 97-107

  Sacristán, José A ^{a,b,c,d,e,f,g}   Kennedy Martin, Tessa ^a,b,c,d,e,f   Rosell, Rafael ^a,b,c,d,e,f   Cardenal, Felipe ^a,b,c,d,e,f   Antón, Antonio ^a,b,c,d,e,f   Lomas, María ^a,b,c,d,e,f   Alberola, Vicente ^a,b,c,d,e,f   Massuti, Bartomeu ^a,b,c,d,e,f   Carrato, Alfredo ^a   Minshall, Michael ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^e DCRandT   (Spain)

^f ELI LILLY AND COMPANY   (United States)

^g Clinical Research Department   (Spain)

Author keywords

Cisplatin; Clinical trial; Cost; Economic; Etoposide; Gemcitabine; Lung cancer; NSCLC

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER RESEARCH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SPAIN;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; ETOPOSIDE; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0034193050     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00120-8     Document Type: Article

References (29)

1. Sacristán J.A. Economic evaluation of drugs alongside clinical trials. Sacristán J.A., Badía X., Rovira J. Pharmacoeconomics: Economic Evaluation of Drugs. 1995;101-114 Editores Médicos, Madrid.
2. Mather D., Sullivan S.D., Parasuraman T.V. Beyond survival: economic analyses of chemotherapy in advanced, inoperable NSCLC. Oncology. 12:1998;199-223.
3. Carney D.M. Management (chemotherapy/best supportive care) of advanced-stage non-small cell lung cancer. Semin. Oncol. 22:1995;58-62.
4. Minshall M.E., Liepa A.M. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer. Am. J. Manag. Care. 4:1998;1591-1602.
5. Abratt R.P., Bezwoda W.R., Falkson G. et al. Efficacy and safety profile of gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1535-1540.
6. Manegold C., Bergmann B., Chemaissani A. et al. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomized phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann. Oncol. 8:1997;525-529.
7. Perng R.P., Chen Y.M., Ming-Liu J. et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J. Clin. Oncol. 15:1997;2097-2102.
8. Noble S., Goa K.L. Gemcitabine. A review of its pharmacological and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 54:1997;447-472.
9. Database of Health Costs in Spain. Version 1.0. SOIKOS. Barcelona: 1997.
10. Sacristán J.A., Day S.J., Navarro O., Ramos J., Hernández J.M. Use of confidence intervals and sample size calculations in health economic studies. Ann. Pharmacother. 29:1995;719-725.
11. Obenchain R.L. ICER conf: Highly Portable C-language Source Code for Confidence Intervals on Incremental Cost-effectiveness Ratios. Pharmaceutical Research and Manufacturers of America (PhRMA), 1996.
12. Cardenal F., López-Cabrerizo M.P., Antón A. et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 17:1999;12-18.
13. Bonsel G.J., Rutten F.F.H., Uyl-de Groot C.A. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur. J. Cancer. 29A(Suppl. 7):1993;S10-S14.
14. Neymark N. Critical reviews of economic analyses in order to make health care decisions for cancer. Ann. Oncol. 9:1998;1167-1172.
15. Copley-Merriman C., Martin C., Johnson N., Sacristán J.A., Drings P.A., Bosanquet N. Economic value of gemcitabine in non-small cell lung cancer. Sem. Oncol. 23(Suppl. 10):1996;90-98.
16. Copley-Merriman C., Corral J., King K., Whiteside R., Voi M., Dorr A. et al. Economic value of gemcitabine compared to cisplatin and etoposide in non small cell lung cancer. Lung Cancer. 14:1996;45-61.
17. Koch P., Johnson N., van Schaik J. et al. Gemcitabine: clinical and economic impact of inoperable non-small cell lung cancer. Anticancer Drugs. 6(Suppl. 6):1995;49-54.
18. Evans W.K. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the population health model lung cancer module. Semin. Oncol. 24(Suppl. 7):1997;56-63.
19. Palmer A.J., Brandt A. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective. Monaldi Arch. Chest Dis. 51:1996;279-288.
20. Benett C.L., Smith T.J., George S.L. et al. Free-riding and the prisoners' dilemma: problems in funding economic analyses of phase III cancer clinical trials. J. Clin. Oncol. 13:1995;2457-2463.
21. Benett C.L., Armitage J.L., Buchner D. et al. Economic analyses in phase III clinical cancer trials. Cancer Invest. 12:1994;336-342.
22. Sacristán J.A. Use of confidence intervals in health economic studies. PharmacoEconomics. 10:1996;432-433.
23. Polsky D., Glick H.A., Eillke R., Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 6:1997;243-252.
24. Sacristán J.A., Obenchain R.L. The negative side of cost-effectiveness analysis. J. Am. Med. Assoc. 277:1997;1931-1933.
25. Buyse M., Piedbois P. On the relationship between response to treatment and survival time. Stat. Med. 15:1996;2797-2812.
26. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-679.
27. Earle C.C., Coyle D., Evans W.K. Cost-effectiveness analysis in oncology. Ann. Oncol. 9:1998;475-482.
28. Schulman K., Yabroff K.R. Measuring the cost-effectiveness of cancer care. Oncology. 9:1995;523-530.
29. Smith J., Hillner B.E., Desch C.E. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J. Nat. Cancer Inst. 85:1993;1460-1474.